inflammation and glp 1 Incretins as Multi–Disease State Treatments Frontiers | Glucagon-like peptide-1 receptor

The patients who do best on these medications aren't the ones with zero cravings

However, drugs that are approved for other indications, like growth hormone for growth deficiencies, are often used off-label for patients with PWS

The clinical trial data from both Phase 2 (Jastreboff et al., NEJM 2023) and Phase 3 (TRIUMPH-4, Eli Lilly press release December 2025) provide a detailed picture of the weight loss trajectory over time

Synthetic oleanane triterpenoids: multifunctional drugs with a broad range of applications for prevention and treatment of chronic disease

Lancet Diabetes Endocrinol 2020;8:37791.ArticlePubMed 31